ST. JOSEPH, Mich., June 17 /PRNewswire/ -- GeneGo, Inc., a leading provider of databases, software and services in systems biology, announced today that they were awarded a Phase I SBIR from National Cancer Institute (NCI) for the development of a platform for functional data analysis in cancer. GeneGo will collaborate with investigators at Dana-Farber Cancer Institute, Boston on the project. The system, MetaMiner (Oncology) will combine pathway and network analysis tools, act as a OMICs data repository and have advanced statistical tools based on functional descriptors.
"MetaMiner (Oncology) is a new generation pathway analysis tool, specifically tailored for biologists, clinicians and chemists working in different cancer areas," said Yuri Nikolsky, CEO of GeneGo and the grant's PI. "Neoplasms are tremendously complex diseases, with many hundreds of perturbed pathways, both in terms of gain and loss of functions. We need to understand in a database structure the causal relationships between the involved pathways and the dynamics of pathway activation during tumorigenesis. These are two main goals of the MetaMiner project."
"There are many 'generic' pathway tools on the market, helpful to some extent in cancer data analysis. However, none of them is centered around cancer biology, which is essential," said Kornelia Polyak, an Associate Professor at Dana-Farber Cancer Institute and a consultant on the grant. "Another focus will be on the development of pathway-based tools for integration of different types of OMICs data -- somatic mutations, high copy number genes, epigenetics, gene expression, proteomics and metabolomics."
About GeneGo
GeneGo develops systems biology technology for life science research. The original computational MetaDiscovery(TM) platform allows an integration and expert analysis of different kinds of experimental data (mRNA expression, proteomics, metabolomics, microRNA assays and other phenotypic data) and relevant bioactive chemistry (metabolites, drugs, other xenobiotics) within the framework of curated biological pathways and networks. GeneGo's flagship product, MetaCore 4.7(TM), assists pharmaceutical scientists in the areas of target selection and validation, identification of biomarkers for disease states and toxicology. The second product, MetaDrug 4.7(TM) is designed for prediction of human metabolism, toxicity and biological effects for novel small molecules compounds. MetaBase(TM) represents the knowledge base for MetaCore. For more information, please visit the company's web site at http://www.genego.com
MetaCore(TM), MetaBase(TM), MetaDrug(TM), MetaLink(TM), MetaDiscovery(TM), MetaTox(TM), MetaMiner(TM) and 1-2-3 Workflow(TM) are trademarks of GeneGo, Inc.
CONTACT: Julie Bryant, VP Business Development and Marketing of GeneGo,
Inc., +1-858-756-7996, julie@genego.com
Web site: http://www.genego.com/
